Good News | Leadingpharm Wins Two Honors: “Top 50 Pharmaceutical R&D Enterprises” and “Law-Abiding and Integrity Enterprise” for 2024–2025

November 2025 – From November 9–11, 2025, the 4th Taishan Pharmaceutical Forum & “2024–2025 Pharmaceutical Industry Information Conference” was successfully held in Jinan, Shandong. At the conference, the highly anticipated “2024–2025 China Pharmaceutical Industry Most Influential List” was unveiled. Leadingpharm successfully won the dual honors of “Top 50 Pharmaceutical R&D Enterprises” and “Law‑Abiding and Integrity Enterprise” for 2024–2025.
 

The All-China Federation of Industry and Commerce’s Pharmaceutical Chamber of Commerce is widely recognized as an authoritative industry organization. Its “China Pharmaceutical Industry Most Influential List” has become a core benchmark for measuring the comprehensive strength of pharmaceutical companies, thanks to its evaluation dimensions covering the entire industrial chain, its innovation‑centered criteria, and its transparent selection process. Leadingpharm’s consecutive inclusion in this list demonstrates the company’s sustained commitment to R&D innovation and reflects the dual recognition from both authoritative bodies and the market regarding its industry value and growth potential.
 

This award marks a high‑level industry endorsement of Leadingpharm’s professional capabilities in pharmaceutical R&D and its compliance‑oriented business philosophy. It is not only an affirmation of the company’s past efforts in innovation and integrity but also an encouragement for future breakthroughs. Going forward, Leadingpharm will continue to provide superior R&D services and uphold standardized management, working hand in hand with industry partners to drive high‑quality development of the pharmaceutical industry and safeguard public health with renewed innovative momentum.

-END-